Here, we provide substantial evidence that Rictor, a well-known component of the mammalian target of rapamycin complex 2 (mTORC2), has significant oncogenic properties in HCC development through p53wt deactivation. This evidence concerns the gene RICTOR and hepatocellular carcinoma.